FY2026 Earnings Forecast for Ardelyx Issued By HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX) – Stock analysts at HC Wainwright boosted their FY2026 earnings estimates for Ardelyx in a research report issued on Friday, February 20th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of $0.18 per share for the year, up from their prior forecast of $0.12. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The business had revenue of $125.22 million for the quarter, compared to analyst estimates of $118.04 million. During the same period last year, the company posted $0.02 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis.

Other research analysts have also issued research reports about the stock. Wedbush reiterated an “outperform” rating and set a $19.00 price objective on shares of Ardelyx in a research note on Monday. TD Cowen reaffirmed a “buy” rating on shares of Ardelyx in a research report on Thursday, January 29th. Citigroup lifted their target price on Ardelyx from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Raymond James Financial reiterated a “strong-buy” rating and set a $19.00 price objective on shares of Ardelyx in a report on Thursday, January 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Ardelyx in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $15.09.

Ardelyx Trading Up 14.1%

NASDAQ:ARDX opened at $6.56 on Monday. Ardelyx has a 12-month low of $3.21 and a 12-month high of $8.40. The firm has a market capitalization of $1.61 billion, a P/E ratio of -26.24 and a beta of 0.57. The business has a 50 day simple moving average of $6.77 and a 200 day simple moving average of $6.14. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.31 and a quick ratio of 4.11.

Institutional Investors Weigh In On Ardelyx

Several institutional investors have recently modified their holdings of ARDX. Mercer Global Advisors Inc. ADV increased its holdings in Ardelyx by 4.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 1,722 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Ardelyx by 26.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,807 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 2,491 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Ardelyx by 0.7% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 347,609 shares of the biopharmaceutical company’s stock valued at $2,027,000 after buying an additional 2,532 shares in the last quarter. Merit Financial Group LLC increased its holdings in shares of Ardelyx by 12.0% during the third quarter. Merit Financial Group LLC now owns 23,680 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 2,537 shares during the period. Finally, Brighton Jones LLC grew its stake in Ardelyx by 25.1% during the third quarter. Brighton Jones LLC now owns 12,701 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 2,550 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.

Insider Activity at Ardelyx

In other news, insider Mike Kelliher sold 9,595 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $5.85, for a total transaction of $56,130.75. Following the transaction, the insider directly owned 364,666 shares in the company, valued at approximately $2,133,296.10. This represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Laura A. Williams sold 8,176 shares of the stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $47,829.60. Following the completion of the transaction, the insider owned 436,082 shares in the company, valued at $2,551,079.70. The trade was a 1.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 136,938 shares of company stock valued at $857,587. Insiders own 4.80% of the company’s stock.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott bought 333,333 shares (~$1.95M) at about $5.84, increasing his stake ~11.2% — a strong insider vote of confidence that can support the stock. Read More.
• Positive Sentiment: Ardelyx announced a multi‑year partnership with the LPGA to raise awareness and reduce stigma around digestive health — a marketing push that could help commercial uptake of XPHOZAH/brand awareness over time. Read More.
• Positive Sentiment: Analyst support remains strong — Wedbush reaffirmed an outperform with a $19 target and other firms (BTIG, HC Wainwright, Jefferies, Citi) have reiterated buys or raised targets, which can attract buyers. Read More. Read More.
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and revenue grew ~7.8% y/y — constructive fundamental data but partially offset by the EPS miss.
• Neutral Sentiment: Post‑results commentary includes valuation and guidance analysis (coverage piece on Yahoo Finance reviewing 2025 results and 2026 guidance) — useful for longer‑term investors assessing upside vs. risk. Read More.
• Negative Sentiment: Ardelyx missed EPS expectations (reported a small loss vs. a modest expected profit), which triggered a post‑earnings pullback and adds short‑term risk for the shares. Read More.
• Negative Sentiment: Multiple insiders (including CEO Michael Raab, CFO Susan Hohenleitner and several executives) sold shares around Feb. 20 (CEO sold ~45,982 shares), which can be perceived as profit‑taking and may pressure sentiment despite the director buy. Read More.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.